CN114515265A - 一种调节荷尔蒙的沉香平衡霜及其制备方法和运用 - Google Patents
一种调节荷尔蒙的沉香平衡霜及其制备方法和运用 Download PDFInfo
- Publication number
- CN114515265A CN114515265A CN202111669339.7A CN202111669339A CN114515265A CN 114515265 A CN114515265 A CN 114515265A CN 202111669339 A CN202111669339 A CN 202111669339A CN 114515265 A CN114515265 A CN 114515265A
- Authority
- CN
- China
- Prior art keywords
- extract
- balance
- cream
- agilawood
- root extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000006071 cream Substances 0.000 title claims abstract description 128
- 239000005556 hormone Substances 0.000 title claims abstract description 53
- 229940088597 hormone Drugs 0.000 title claims abstract description 53
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 33
- 238000002360 preparation method Methods 0.000 title claims abstract description 30
- 241001533085 Aquilaria sinensis Species 0.000 title description 2
- 239000000284 extract Substances 0.000 claims abstract description 160
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 45
- 239000002994 raw material Substances 0.000 claims abstract description 19
- 244000281702 Dioscorea villosa Species 0.000 claims abstract description 17
- 244000179560 Prunella vulgaris Species 0.000 claims abstract description 15
- 240000001341 Reynoutria japonica Species 0.000 claims abstract description 15
- 235000018167 Reynoutria japonica Nutrition 0.000 claims abstract description 15
- 240000004534 Scutellaria baicalensis Species 0.000 claims abstract description 15
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims abstract description 15
- 239000003755 preservative agent Substances 0.000 claims abstract description 14
- 230000002335 preservative effect Effects 0.000 claims abstract description 13
- 235000008113 selfheal Nutrition 0.000 claims abstract description 13
- 239000012071 phase Substances 0.000 claims description 47
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims description 44
- 238000003756 stirring Methods 0.000 claims description 42
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 34
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims description 22
- 229960001948 caffeine Drugs 0.000 claims description 22
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims description 22
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 22
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 20
- -1 and the like Chemical compound 0.000 claims description 19
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 19
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 19
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 18
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 18
- AEMOLEFTQBMNLQ-VANFPWTGSA-N D-mannopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-VANFPWTGSA-N 0.000 claims description 17
- AIPVRBGBHQDAPX-UHFFFAOYSA-N hydroxy(methyl)silane Chemical compound C[SiH2]O AIPVRBGBHQDAPX-UHFFFAOYSA-N 0.000 claims description 17
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 17
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 17
- 229940100460 peg-100 stearate Drugs 0.000 claims description 17
- 229940032094 squalane Drugs 0.000 claims description 17
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 claims description 17
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 16
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 16
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 16
- 244000042664 Matricaria chamomilla Species 0.000 claims description 16
- 235000007232 Matricaria chamomilla Nutrition 0.000 claims description 16
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 16
- XSTXAVWGXDQKEL-UHFFFAOYSA-N Trichloroethylene Chemical compound ClC=C(Cl)Cl XSTXAVWGXDQKEL-UHFFFAOYSA-N 0.000 claims description 16
- 229940072056 alginate Drugs 0.000 claims description 16
- 235000010443 alginic acid Nutrition 0.000 claims description 16
- 229920000615 alginic acid Polymers 0.000 claims description 16
- 229940059958 centella asiatica extract Drugs 0.000 claims description 16
- 235000004879 dioscorea Nutrition 0.000 claims description 16
- 235000010445 lecithin Nutrition 0.000 claims description 16
- 239000000787 lecithin Substances 0.000 claims description 16
- 229940067606 lecithin Drugs 0.000 claims description 16
- 229960005323 phenoxyethanol Drugs 0.000 claims description 16
- 239000001331 rosmarinus officinalis leaf Substances 0.000 claims description 16
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 16
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 16
- 239000011732 tocopherol Substances 0.000 claims description 16
- 229930003799 tocopherol Natural products 0.000 claims description 16
- 235000010384 tocopherol Nutrition 0.000 claims description 16
- 229960001295 tocopherol Drugs 0.000 claims description 16
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 16
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 15
- 229920002125 Sokalan® Polymers 0.000 claims description 15
- 229960001631 carbomer Drugs 0.000 claims description 15
- 235000007866 Chamaemelum nobile Nutrition 0.000 claims description 14
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 14
- 235000010469 Glycine max Nutrition 0.000 claims description 14
- 244000068988 Glycine max Species 0.000 claims description 14
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 14
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 14
- 229940075529 glyceryl stearate Drugs 0.000 claims description 14
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 claims description 14
- GOMNOOKGLZYEJT-UHFFFAOYSA-N isoflavone Chemical compound C=1OC2=CC=CC=C2C(=O)C=1C1=CC=CC=C1 GOMNOOKGLZYEJT-UHFFFAOYSA-N 0.000 claims description 14
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 claims description 14
- 235000008696 isoflavones Nutrition 0.000 claims description 14
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 claims description 13
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 claims description 13
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 claims description 13
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 claims description 13
- 229930182478 glucoside Natural products 0.000 claims description 13
- 150000008131 glucosides Chemical class 0.000 claims description 13
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 13
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 13
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 12
- 238000010438 heat treatment Methods 0.000 claims description 12
- 229940092665 tea leaf extract Drugs 0.000 claims description 12
- 238000005303 weighing Methods 0.000 claims description 12
- 229940081733 cetearyl alcohol Drugs 0.000 claims description 11
- 239000003995 emulsifying agent Substances 0.000 claims description 11
- PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical compound [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 claims description 11
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 claims description 9
- 238000004945 emulsification Methods 0.000 claims description 8
- 235000011187 glycerol Nutrition 0.000 claims description 8
- 235000005903 Dioscorea Nutrition 0.000 claims description 6
- 235000000504 Dioscorea villosa Nutrition 0.000 claims description 6
- 239000008346 aqueous phase Substances 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 6
- 230000001804 emulsifying effect Effects 0.000 claims description 6
- 239000004721 Polyphenylene oxide Substances 0.000 claims description 4
- 229920000570 polyether Polymers 0.000 claims description 4
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 claims description 2
- 235000010674 Prunella vulgaris Nutrition 0.000 claims description 2
- 229960001344 methylphenidate Drugs 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 3
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 64
- 206010000496 acne Diseases 0.000 abstract description 16
- 208000002874 Acne Vulgaris Diseases 0.000 abstract description 15
- 230000002087 whitening effect Effects 0.000 abstract description 10
- 238000007254 oxidation reaction Methods 0.000 abstract description 9
- 206010061218 Inflammation Diseases 0.000 abstract description 8
- 230000001965 increasing effect Effects 0.000 abstract description 8
- 230000004054 inflammatory process Effects 0.000 abstract description 8
- 230000002401 inhibitory effect Effects 0.000 abstract description 8
- 230000003647 oxidation Effects 0.000 abstract description 8
- 239000000419 plant extract Substances 0.000 abstract description 8
- 230000037303 wrinkles Effects 0.000 abstract description 8
- 238000013329 compounding Methods 0.000 abstract description 7
- 241000894006 Bacteria Species 0.000 abstract description 6
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 6
- 230000032683 aging Effects 0.000 abstract description 6
- 208000026935 allergic disease Diseases 0.000 abstract description 6
- 230000007815 allergy Effects 0.000 abstract description 6
- 206010030113 Oedema Diseases 0.000 abstract description 5
- 230000003467 diminishing effect Effects 0.000 abstract description 5
- 231100000241 scar Toxicity 0.000 abstract description 5
- 208000032544 Cicatrix Diseases 0.000 abstract description 4
- 230000037387 scars Effects 0.000 abstract description 4
- 239000002738 chelating agent Substances 0.000 abstract description 3
- 241000167550 Centella Species 0.000 abstract description 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 2
- 244000269722 Thea sinensis Species 0.000 abstract 1
- 208000011318 facial edema Diseases 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 69
- 230000000052 comparative effect Effects 0.000 description 45
- 239000003205 fragrance Substances 0.000 description 40
- 206010037888 Rash pustular Diseases 0.000 description 34
- 208000029561 pustule Diseases 0.000 description 34
- 206010033733 Papule Diseases 0.000 description 33
- 239000003921 oil Substances 0.000 description 26
- 235000019198 oils Nutrition 0.000 description 25
- 238000012360 testing method Methods 0.000 description 20
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 16
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- 230000003020 moisturizing effect Effects 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 230000003385 bacteriostatic effect Effects 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 8
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 8
- 229960002216 methylparaben Drugs 0.000 description 8
- 229920001296 polysiloxane Polymers 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 230000006870 function Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 208000020154 Acnes Diseases 0.000 description 6
- 239000003974 emollient agent Substances 0.000 description 6
- 239000000262 estrogen Substances 0.000 description 6
- 229940011871 estrogen Drugs 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 238000004140 cleaning Methods 0.000 description 5
- 230000007547 defect Effects 0.000 description 5
- 229940072008 glycyrrhiza glabra extract Drugs 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 235000003687 soy isoflavones Nutrition 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 241001122767 Theaceae Species 0.000 description 4
- 230000003712 anti-aging effect Effects 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 229940008099 dimethicone Drugs 0.000 description 4
- 230000001815 facial effect Effects 0.000 description 4
- 230000003405 preventing effect Effects 0.000 description 4
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 3
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 3
- 230000003266 anti-allergic effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical group O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 3
- 229960003321 baicalin Drugs 0.000 description 3
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 230000001568 sexual effect Effects 0.000 description 3
- 206010040882 skin lesion Diseases 0.000 description 3
- 231100000444 skin lesion Toxicity 0.000 description 3
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- 238000010998 test method Methods 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 2
- 240000005250 Chrysanthemum indicum Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 206010014970 Ephelides Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- 208000019255 Menstrual disease Diseases 0.000 description 2
- 244000178231 Rosmarinus officinalis Species 0.000 description 2
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 102000003425 Tyrosinase Human genes 0.000 description 2
- 108060008724 Tyrosinase Proteins 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003255 anti-acne Effects 0.000 description 2
- 239000002216 antistatic agent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 230000003054 hormonal effect Effects 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 230000001050 lubricating effect Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000035699 permeability Effects 0.000 description 2
- 239000003075 phytoestrogen Substances 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- 230000037380 skin damage Effects 0.000 description 2
- 230000037394 skin elasticity Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- HDXIQHTUNGFJIC-UHFFFAOYSA-N (25R)-spirost-5-en-3beta-ol 3-O-<O-alpha-L-rhamnopyranosyl-(1-->2)-beta-D-glucopyranoside> Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC1OC(CO)C(O)C(O)C1OC1OC(C)C(O)C(O)C1O HDXIQHTUNGFJIC-UHFFFAOYSA-N 0.000 description 1
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 1
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- YJLUBHOZZTYQIP-UHFFFAOYSA-N 2-[5-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]-1,3,4-oxadiazol-2-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1=NN=C(O1)CC(=O)N1CC2=C(CC1)NN=N2 YJLUBHOZZTYQIP-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 102100030310 5,6-dihydroxyindole-2-carboxylic acid oxidase Human genes 0.000 description 1
- 101710163881 5,6-dihydroxyindole-2-carboxylic acid oxidase Proteins 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000030523 Catechol oxidase Human genes 0.000 description 1
- 108010031396 Catechol oxidase Proteins 0.000 description 1
- 235000018959 Chrysanthemum indicum Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- VNONINPVFQTJOC-RXEYMUOJSA-N Collettiside III Natural products O([C@@H]1[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O2)[C@H](CO)O[C@@H]1O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]5[C@H](C)[C@@]6(O[C@H]5C4)OC[C@H](C)CC6)CC3)CC=2)CC1)[C@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O1 VNONINPVFQTJOC-RXEYMUOJSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010013082 Discomfort Diseases 0.000 description 1
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- OVSQVDMCBVZWGM-SJWGPRHPSA-N Hyperin Natural products O[C@H]1[C@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-SJWGPRHPSA-N 0.000 description 1
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 1
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000153955 Reynoutria sachalinensis Species 0.000 description 1
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 description 1
- 239000010404 Scutellaria baicalensis extract Substances 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 206010058679 Skin oedema Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 206010040925 Skin striae Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- DWCSNWXARWMZTG-UHFFFAOYSA-N Trigonegenin A Natural products CC1C(C2(CCC3C4(C)CCC(O)C=C4CCC3C2C2)C)C2OC11CCC(C)CO1 DWCSNWXARWMZTG-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000001153 anti-wrinkle effect Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001217 buttock Anatomy 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000012627 chemopreventive agent Substances 0.000 description 1
- 229940124443 chemopreventive agent Drugs 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- VNONINPVFQTJOC-ZGXDEBHDSA-N dioscin Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H](O)[C@@H](O)[C@H](C)O1)O)O[C@@H]1CC2=CC[C@H]3[C@@H]4C[C@H]5[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@@H]([C@]1(OC[C@H](C)CC1)O5)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O VNONINPVFQTJOC-ZGXDEBHDSA-N 0.000 description 1
- CJNUQCDDINHHHD-APRUHSSNSA-N dioscin Natural products C[C@@H]1CC[C@@]2(OC1)O[C@H]3C[C@H]4[C@@H]5CC=C6C[C@H](CC[C@@H]6[C@H]5CC[C@]4(C)[C@H]3[C@@H]2C)O[C@@H]7O[C@H](CO)[C@@H](O[C@@H]8O[C@@H](C)[C@H](O)[C@@H](O)[C@H]8O)[C@H](O)[C@H]7O[C@@H]9O[C@@H](C)[C@H](O)[C@@H](O)[C@H]9O CJNUQCDDINHHHD-APRUHSSNSA-N 0.000 description 1
- WQLVFSAGQJTQCK-VKROHFNGSA-N diosgenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CC[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 WQLVFSAGQJTQCK-VKROHFNGSA-N 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- VJNCICVKUHKIIV-UHFFFAOYSA-N dopachrome Chemical compound O=C1C(=O)C=C2NC(C(=O)O)CC2=C1 VJNCICVKUHKIIV-UHFFFAOYSA-N 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003560 epithelium corneal Anatomy 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000004996 female reproductive system Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- LBQIJVLKGVZRIW-ZDUSSCGKSA-N glabridin Chemical compound C1([C@H]2CC3=CC=C4OC(C=CC4=C3OC2)(C)C)=CC=C(O)C=C1O LBQIJVLKGVZRIW-ZDUSSCGKSA-N 0.000 description 1
- 229940093767 glabridin Drugs 0.000 description 1
- PMPYOYXFIHXBJI-ZDUSSCGKSA-N glabridin Natural products C1([C@H]2CC=3C=CC4=C(C=3OC2)CCC(O4)(C)C)=CC=C(O)C=C1O PMPYOYXFIHXBJI-ZDUSSCGKSA-N 0.000 description 1
- LBQIJVLKGVZRIW-UHFFFAOYSA-N glabridine Natural products C1OC2=C3C=CC(C)(C)OC3=CC=C2CC1C1=CC=C(O)C=C1O LBQIJVLKGVZRIW-UHFFFAOYSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- NQYPTLKGQJDGTI-FCVRJVSHSA-N hyperoside Natural products OC[C@H]1O[C@@H](OC2=C(Oc3cc(O)cc(O)c3[C@H]2O)c4ccc(O)c(O)c4)[C@H](O)[C@@H](O)[C@H]1O NQYPTLKGQJDGTI-FCVRJVSHSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000036564 melanin content Effects 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960003476 methylparaben sodium Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015816 nutrient absorption Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 229940100243 oleanolic acid Drugs 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000004789 organ system Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- VNONINPVFQTJOC-UHFFFAOYSA-N polyphyllin III Natural products O1C2(OCC(C)CC2)C(C)C(C2(CCC3C4(C)CC5)C)C1CC2C3CC=C4CC5OC(C(C1O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C1OC1OC(C)C(O)C(O)C1O VNONINPVFQTJOC-UHFFFAOYSA-N 0.000 description 1
- 206010036601 premature menopause Diseases 0.000 description 1
- 208000017942 premature ovarian failure 1 Diseases 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000006920 protein precipitation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- OVSQVDMCBVZWGM-DTGCRPNFSA-N quercetin 3-O-beta-D-galactopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-DTGCRPNFSA-N 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- BBFYUPYFXSSMNV-UHFFFAOYSA-N quercetin-7-o-galactoside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC(O)=C2C(=O)C(O)=C(C=3C=C(O)C(O)=CC=3)OC2=C1 BBFYUPYFXSSMNV-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940092258 rosemary extract Drugs 0.000 description 1
- 235000020748 rosemary extract Nutrition 0.000 description 1
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 239000010686 shark liver oil Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 1
- 229940096998 ursolic acid Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
- A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/58—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
- A61K8/585—Organosilicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/733—Alginic acid; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/86—Polyethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
- A61K8/89—Polysiloxanes
- A61K8/891—Polysiloxanes saturated, e.g. dimethicone, phenyl trimethicone, C24-C28 methicone or stearyl dimethicone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/524—Preservatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
Abstract
本发明提供了一种调荷尔蒙的沉香平衡霜及其制备方法和运用,涉及护肤品技术领域;该平衡霜通过薯蓣根提取物、夏枯草提取物、积雪草提取物、虎杖根提取物、黄芩根提取物、茶叶提取物、沉香提取物等天然植物提取物与防腐剂、螯合剂等原料复配所得;制得的平衡霜对调节女性荷尔蒙具有极为显著的作用,同时具有极强的抗菌消炎、补水保湿、抗氧化、淡纹祛斑、舒缓抗敏、祛痘抑痘、美白祛斑、延缓衰老、修复疤痕、增加光泽度、消除面部水肿或者浮肿等作用;本发明中除天然植物提取物外,所有化学试剂的风险系数均≤4,处于安全系数较高的范围,且制成的平衡霜质地细腻温和、清爽不油腻,广泛适用于各类女性荷尔蒙失调人群。
Description
技术领域
本发明涉及护肤品技术领域,特别是一种调节荷尔蒙的沉香平衡霜及其制备方法和运用。
背景技术
荷尔蒙是人体内分泌系统分泌的、能调节生理平衡的激素的总称,它对机体的各种物质代谢(包括糖、脂肪、蛋白质、水、电解质、矿物质等)、生长、发育、繁殖、性别、性欲和性活动等起重要的调节作用,对维持人体正常的生理功能十分重要。另外,荷尔蒙不但影响一个正常人的生长、发育及情绪表现,更是维持体内各器官系统均衡动作的重要因素。
女性荷尔蒙,即雌性激素,可以使皮肤保持水分和弹性、促进皮肤新陈代谢及血液循环,产生并维持女性的第二性征。女性荷尔蒙能够使女性保持女人味、延缓衰老,有人将女性荷尔蒙的多少用于衡量女性青春的长短,由此可知女性荷尔蒙对于女性而言极为重要,而一旦荷尔蒙失衡身体便会出现各种病变,如出现卵巢早衰、月经失调、不孕不育、围绝经期,机体免疫力下降,骨质疏松、潮热多汗,失眠烦躁,腰酸背痛,皮肤色斑,腰腹肥胖等症状。
目前,女性荷尔蒙失调人群常口服雌性激素类药物进行治疗,虽然其对于调节女性荷尔蒙具有一定的作用,但是激素类药物的依赖性强、常常不能从根本上解决女性荷尔蒙失调的问题,且长期服用易使体内激素分泌失调,肝功能损害、脂质代谢紊乱,甚至会诱发乳腺癌等。
发明内容
针对现有技术的不足,本发明提出了一种调节荷尔蒙的沉香平衡霜及其制备方法和运用;该平衡霜将传统中草药特色和现代医学研究相结合,通过薯蓣根提取物、夏枯草提取物、积雪草提取物、虎杖根提取物、黄芩根提取物、茶叶提取物、光果甘草根提取物、母菊花提取物、沉香提取物等天然植物提取物与防腐剂、螯合剂等原料复配所得;将制得的平衡霜涂抹于女性身体,能够实现调节女性荷尔蒙的作用,此外该平衡霜还具有抗菌消炎、补水保湿、抗氧化、淡纹祛斑、舒缓抗敏、祛痘抑痘、美白祛斑、延缓衰老、修复疤痕、增加皮肤光泽度、消除浮肿等作用;本发明中除天然植物提取物外,所有化学试剂的风险系数均≤4,安全系数极高。
本发明是通过以下技术方案来实现的:
一种调节荷尔蒙的沉香平衡霜,所述平衡霜的组分及质量比为:硅氧烷三醇藻酸酯3-4%、咖啡因0.2-0.3%、羟苯甲酯钠0.01-0.02%、甲基硅烷醇甘露糖醛酸酯4-5%、甘油聚醚-261.5-3%、大豆异黄酮1-1.5%、生育酚0.5-2%、卵磷脂1-1.5%、薯蓣根提取物1.5-2.5%、夏枯草提取物1-2%、积雪草提取物0.002-0.004%、虎杖根提取物0.003-0.004%、黄芩根提取物0.003-0.005%、茶叶提取物0.002-0.003%、光果甘草根提取物0.002-0.004%、母菊花提取物0.002-0.004%、迷迭香叶提取物0.002-0.004%、沉香提取物0.04-0.05%、透明质酸钠0.2-0.3%、丁二醇11.4-11.7、角鲨烷5-7%、辛酸/癸酸甘油三酯4-6%、聚二甲基硅氧烷2-3%、卡波姆0.15-0.3%、三乙醇胺0.2-0.25%、EDTA二钠0.04-0.05%、防腐剂0.51-0.65%、乳化剂3-4.5%、余量为水。
上述方案中,主要以薯蓣根提取物、夏枯草提取物、积雪草提取物、虎杖根提取物、黄芩根提取物、茶叶提取物、光果甘草根提取物、母菊花提取物、迷迭香叶提取物、沉香提取物、硅氧烷三醇藻酸酯、咖啡因、羟苯甲酯钠、甲基硅烷醇甘露糖醛酸酯、甘油聚醚-26、大豆异黄酮、生育酚、卵磷脂、透明质酸钠、丁二醇、角鲨烷、辛酸/癸酸甘油三酯、聚二甲基硅氧烷作为皮肤调理剂;以卡波姆作为PH调节剂;以EDTA二钠作为螯合剂。
其中作为皮肤调理剂的各成分作用如下:
薯蓣根提取物:含多种氨基酸以及薯蓣皂甙元、多巴胺、多酚氧化酶、尿囊素、多种甾醇等,有保湿,滋润清洁和杀菌等作用;此外,薯蓣根提取物中还含有植物雌激素,具有雌激素样作用,能够使人体内雌激素水平保持在最佳水平,从而达到美容美白、促进乳腺生长、缓解更年期及经期多种不适,还具有降血脂预防心血管、抗炎保肝等作用;从而实现调节女性荷尔蒙的作用。
夏枯草提取物:含有三萜皂苷、芸香苷、金丝桃苷等苷类物质及熊果酸、咖啡酸、游离齐敦果酸等有机酸,能保湿护肤,打开黑色素集合斑点,抑制络氨酸酶的活性,起到美白祛斑的效果。具有保湿护肤,美白祛斑的作用;此外,夏枯草提取物还能使人镇静、促进睡眠,进而维持人体机能的顺利运行。
积雪草提取物:积雪草提取物是一种全水溶的天然活性成分,可以刺激成纤维细胞增殖并激活SMAD信号传导途径,增加I型胶原蛋白的产生以及减少细纹和炎症反应的形成;
可以减少前炎症介质(IL-1,MMP-1)的产生,提高和修复肌肤自身屏障功能;还可显著提高胶原蛋白和细胞层纤连蛋白,且能够显著增加角质层的水合程度,进而具有修复红血丝、增强皮肤水分的功能;此外,还具有抗氧化,抗衰老、疤痕修复、抗炎,抗菌和抗癌活性。
虎杖根提取物:能够减少黑色素含量,具有美白功能;具有抗氧化、抗皱和抗菌作用。
黄芩提取物:主要成分为黄芩苷,具有抗炎、抗变态反应作用;吸收紫外线,清除氧自由基,抑制黑色素的生成,让肌肤干净平滑,对于已晒伤的皮肤,有一定修复作用;能中和释放的组胺具抗过敏作用;具有抗衰老和保湿的作用;此外,黄芩提取物中的黄芩苷锌和黄芩苷铜对超氧自由基有明显的清除作用,保护皮肤细胞不受氧自由基过度氧化,从而增加皮肤新陈代谢、增加皮肤弹性、以及抗皱性和抗衰老性。
茶叶提取物:主要成分为茶多酚,为纯天然提取产物,具有健美肌肤、延缓皮肤衰老等功能,能够清除体内的各种自由基,达到抗氧化的效果;此外,茶多酚还具有收敛性,能够使蛋白质沉淀变性,故具有较强的抗菌作用。
光果甘草提取物:具有抗菌消炎、舒缓抗敏、抗氧化、抗衰老、防紫外线、防晒、美白祛斑等功效;在全球化妆品界,光甘草定被誉为“美白黄金”的功效;它能抑制酪氨酸酶的活性,又能抑制多巴色素互变和DHICA氧化酶的活性,具有与SOD(过氧化物歧化酶)相似的清除氧自由基的能力,具有与维生素E相近的抗氧自由基能力;此外,光果甘草提取物还有抑制食欲的作用,它能减少脂肪却又不减轻体重,能够使女性维持身体健康。
母菊花提取物:具有使皮肤大量补水、调节皮肤的水油平衡的作用;因其含有氨基酸,可以快速有效的缓解肌肤深层保湿的的作用,减少面部细纹的产生;同时具有消炎抗菌的作用,可以减少痘痘的产生,减少皮肤发红过敏。
迷迭香叶提取物:具有极好的抗氧化性能,其对纤维芽细胞等具有一定的增殖作用、对弹性蛋白酶、胶原蛋白酶具有一定的抑制作用,即迷迭香提取物具有活肤抗衰、以及抗炎和收敛的作用。
沉香提取物:沉香具有镇静、抗心律失常、抑制中枢神经系统等作用;同时具有保湿护肤、抗菌消炎的作用,此外,沉香作为众香之首,香气浓郁,能够促进新陈代谢,进而促进女性解郁开气,心胸豁达;同时其为天然香精,能够克服人工香精对敏感肌肤造成不利影响的缺陷;同时沉香、迷迭香以及上述中药提取物的复配对激发女性自行产生女性荷尔蒙具有积极的作用。
硅氧烷三醇藻酸酯:柔润剂,表面活性剂,硅表面活性剂-非离子型,具有优良的吸附、分散能力,其与光果甘草提取物进行复配后,能够克服其本身对皮肤和眼睛具有刺激性的缺陷。
咖啡因:抗氧化剂,可促进其他活性物质的渗透和吸收。此外,薯蓣提取物和大豆异黄酮中含有植物雌激素,咖啡因与雌激素组合制成平衡霜对粉刺有抑制和治疗作用,因此通过咖啡因和薯蓣提取物、大豆异黄酮等复配能够实现祛痘和抑痘的目的,对于维持肌肤光滑具有积极作用;此外咖啡因能有效促脂解,与迷迭香提取物配合可用于消除皮肤浮肿,实现减脂紧肤的效果。
羟苯甲酯钠:表面活性剂,防腐剂,提高水溶性。
甲基硅烷醇甘露糖醛酸酯:柔润剂,肤感调节剂,抗静电剂。甲基硅烷醇甘露糖醛酸酯为有机硅成分,能够增加产品涂抹在皮肤上的顺滑感。
甘油聚醚-26:保湿剂、润滑剂以及泡沫调节剂。甘油聚醚-26是26个EO的甘油聚合物,其1%的添加量的保湿效果要强于3%的甘油,能克服甘油半干状态带来的不愉快的粘腻感。
大豆异黄酮:保湿剂,健美功效成分,改善皮肤水分及弹性状况;大豆异黄酮作为天然雌激素,具有与雌激素相似的结构,其直接影响激素分泌、代谢生物学活性、蛋白质合成、生长因子活性,是天然的癌症化学预防剂。
生育酚:具有保湿和抗氧化作用。
卵磷脂:具有保湿和抗氧化作用。
透明质酸钠:天然存在于角膜皮中,可吸收其本身重量1000倍水分,以达到通过保留皮肤水分、阻止水分经表皮流失,以及当皮肤受到损伤时的屏障修复,令皮肤使用后不会感到干燥,增加光泽,它可以改善皮肤营养代谢,使皮肤柔、光滑、去皱、增加弹性、防止衰老,在保湿的同时又是良好的透皮吸收促进剂。与上述提取物配合使用,可以促进营养吸收、增强功效。
丁二醇:抗菌剂,保湿剂,溶剂,质地温和之多元醇类。在护肤品中常用作小分子保湿成份,可将水分留在角质层,有良好的吸湿性,可吸收相当于本身质量的12.5%(相对湿度50%)和38.5%(相对湿度80%)的水分,同时也有一定的抑菌作用。
角鲨烷:柔润剂,角鲨烷提取自深海鲨鱼肝脏或橄榄油中,是皮肤一种天然成分,具有较好抗氧化力和刺激免疫力,能快速地与肌肤内的水分和油脂相溶,形成天然的皮肤保护屏障,稳定性极佳,不会与空气、紫外线等发生氧化作用,能有效保护皮肤不受外界物质的侵害,极佳的渗透力,高效的携氧性,能调整肌肤的水油平衡,避免肌肤粗糙、暗沉,恢复肌肤原本的柔嫩触感。
辛酸/癸酸甘油三酯:溶剂,柔润剂,辛酸/癸酸甘油三酯是高清爽度无味油脂,属棕榈油或椰子油的衍生物,由于它和人体皮肤有兼容的特征,它有着不油腻质感,加入乳霜或乳液中可改进其延伸性,有润滑和使肌肤柔软的效果,并有过滤紫外光的功能。
聚二甲基硅氧烷:成膜剂,柔润剂,润滑性能好,涂敷皮肤后能形成一层均匀的具有防水性的保护膜,但又没有任何粘性和油腻的感觉,光泽性好。抗紫外线辐射的性能好。它在紫外线下不会氧化变质而引起对皮肤刺激作用。抗静电性能好,并有明显的防尘效果,透气性好,即使在皮肤上形成硅氧烷膜也不影响汗液排出。此外,聚二甲基硅氧烷具有缓释定香作用,能够延长沉香提取物的香期以及提高香味稳定性。
本发明通过将上述各原料按照一定的比例复配,制得一款具有调节女性荷尔蒙、抗菌消炎、抗氧化、收敛、补水淡纹、保湿润肤、滋润清洁、舒缓抗敏、祛痘抑痘、防紫外线、美白祛斑、延缓衰老、增强皮肤弹性和抗皱性、修复疤痕、增加光泽度、消除浮肿、减脂紧肤、香味持久等的平衡霜。
优选的,所述平衡霜的组分即质量比为:硅氧烷三醇藻酸酯3.55%、咖啡因0.2%、羟苯甲酯钠0.011%、甲基硅烷醇甘露糖醛酸酯4.9935%、甘油聚醚-26 2%、大豆异黄酮1%、生育酚1%、卵磷脂1%、薯蓣根提取物2%、夏枯草提取物1%、积雪草提取物0.003%、虎杖根提取物0.003%、黄芩根提取物0.003%、茶叶提取物0.003%、光果甘草根提取物0.003%、母菊花提取物0.003%、迷迭香叶提取物0.003%、沉香提取物0.05%、透明质酸钠0.2%、丁二醇11.5455%、角鲨烷5%、辛酸/癸酸甘油三酯5%、聚二甲基硅氧烷2%、卡波姆0.2%、三乙醇胺0.2%、、EDTA二钠0.05%、防腐剂0.6%、乳化剂4%、余量为水。
优选的,所述防腐剂的组分及其在所述平衡霜中的质量比为:苯氧乙醇0.4-0.5%、羟苯甲酯0.07-0.13%、羟苯乙酯0.04-0.05%。
优选的,所述防腐剂的组分及其在所述平衡霜中的质量比为:苯氧乙醇0.432%、羟苯甲酯0.12%、羟苯乙酯0.048%。
羟苯甲酯、羟苯乙酯均为paraben类防腐剂,具有极强的杀菌作用,其在使用中,对用量的要求较高,添加量不当对皮肤极易造成伤害,通过其与中药提取物之间的复配,以及调控配方之间的用量,能够克服其对皮肤造成刺激、过敏等不利影响的缺陷。此外,苯氧乙醇主要作用也为防腐剂和抗菌剂,由于具有一定的乳化作用,对产品的黏度影响较大。
优选的,所述乳化剂的组分及其在所述平衡霜中的质量比为:鲸蜡硬脂醇1.5-1.7%、鲸蜡硬脂基葡糖苷0.4-0.5%、甘油硬脂酸酯0.9-1%、PEG-100硬脂酸酯1-1.2%。
优选的,所述乳化剂的组分及其在所述平衡霜中的质量比为:鲸蜡硬脂醇1.6%、鲸蜡硬脂基葡糖苷0.4%、甘油硬脂酸酯1%、PEG-100硬脂酸酯1%。
PEG-100硬脂酸酯、甘油硬脂酸酯、鲸蜡硬脂基葡糖苷、鲸蜡硬脂醇按照一定配比加入平衡霜后,能够使平衡霜中的所有成分充分混合,确保平衡霜粘稠度、均匀度以及稳定性达至最佳。其中,因PEG-100硬脂酸酯和甘油硬脂酸酯均具有致痘性,易引发皮肤过敏,因此在配伍方面要求过高,通过使其与上述中药提取物按照合理配比进行配伍,能够明显克服PEG-100硬脂酸酯和甘油硬脂酸酯的致痘性等缺陷,确保其对皮肤不会造成伤害。
此外,本发明还提供一种调节荷尔蒙的沉香平衡霜的制备方法,包括如下步骤:
S1油相制备:按重量百分比称取原料,将角鲨烷、辛酸/癸酸甘油三酯、聚二甲基硅氧烷、乳化剂、硅氧烷三醇藻酸酯、甲基硅烷醇甘露糖醛酸酯、甘油聚醚-26、大豆异黄酮、生育酚、卵磷脂、防腐剂加入油相锅中,以50-80转/分搅拌并同时加热至76-78℃,并其后在76-78℃以50-80转/分搅拌20-30分钟,得到油相;
水相制备:按重量百分比称取原料,将丁二醇、羟苯甲酯钠、卡波姆、三乙醇胺、EDTA二钠和水加入水相锅中,以50-80转/分搅拌并同时加热至76-82℃,并其后在76-82℃以50-80转/分搅拌20-30分钟,得到水相;
S2乳化:将所述油相和水相加入乳化锅中,在76-78℃以50-80转/分搅拌10-15分钟后,以3000-4000转/分均质10-15分钟,再以50-80转/分搅拌并降温至40-45℃,其次加入透明质酸钠、咖啡因、薯蓣根提取物、夏枯草提取物、积雪草提取物、虎杖根提取物、黄芩根提取物、茶叶提取物、光果甘草根提取物、母菊花提取物、迷迭香叶提取物和沉香提取物,以50-80转/分搅拌30-40分钟,得到平衡霜。
本发明先将油相原料和水相原料分别混合后,再将油相和水相与剩余组分进行乳化,能够使原料充分混合,同时提高平衡霜的稳定性和均匀性。因苯氧乙醇在80℃以下稳定,因此在制备油相以及乳化过程中,温度均控制在76-78℃,既能确保油相原料与其他原料之间混合均匀,也能确保苯氧乙醇在平衡霜中的稳定性。
此外,本发明还提供一种调节荷尔蒙的沉香平衡霜的运用,主要用于调节、平衡或者改善女性荷尔蒙,该平衡霜有两种使用方法,其一:直接将该平衡霜涂抹于女性身体,其后用手轻拍直至平衡霜完全被皮肤吸收;其二:先将该平衡霜涂抹于女性身体,其后结合按摩或者推拿手法,使该平衡霜作为按摩霜或者推拿霜使用,上述两种方法均能实现对女性荷尔蒙的调节作用,相比而言,第二种方法效果更加突出;此外,因该平衡霜温和无刺激,在日常使用中,也可作为面霜使用。
本发明的有益效果是:
本发明提供一种由传统中药提取物和现代药物按照一定比例复配的调节女性荷尔蒙的平衡霜,该平衡霜中因各成分相互协同作用,使制备的平衡霜不仅本身能够提供天然的植物雌性激素,而且能够促进人体自发产生女性荷尔蒙,进而实现调节、改善和平衡女性荷尔蒙的目的,对于该类人群(①DHEA(性黄金)缺乏导致的性欲下降及臀部松弛、下垂、淤堵;②夫妻性生活不愉快;③女性宫寒导致的月经不调及,各种妇科疾病;④孕激素不平衡导致的不孕不育;⑤妇科亚健康人群)更具显著的作用;此外,该平衡霜无需口服,只需涂抹于女性身体便可实现调节荷尔蒙的目的,且所有成分的风险指数均≤4,安全无副作用。
以下是本发明中的平衡霜能够发挥调节女性荷尔蒙的具体原因:
(1)具有抗菌消炎、美白祛斑、舒缓抗敏、祛痘抑痘、修复疤痕等功效,能使皮肤长久保持紧致光滑;
(2)具有抗氧化、延缓衰老、防紫外线、抗皱、收敛、补水淡纹、保湿润肤、滋润清洁、镇定等作用,能显著清除人体自由基,改善人体睡眠,促进人体新陈代谢,增强皮肤弹性和光泽度,全方位调节女性生殖系统功能,确保各机能顺利运作,缓解更年期症状,调节两性幸福状态等作用;
(3)具有消除浮肿、减脂紧肤等作用;能够使女性维持完美身材,提升女性自信以及女人味。
具体实施方式
下面结合实施例进一步详细描述本发明的技术方案,但本发明的保护范围不局限于以下。
一、实施例与对比例
实施例1
按重量百分比计,平衡霜中的配方和配比为:
角鲨烷5%、辛酸/癸酸甘油三酯4%、聚二甲基硅氧烷3%、鲸蜡硬脂醇1.5%、鲸蜡硬脂基葡糖苷0.5%、甘油硬脂酸酯1%、PEG-100硬脂酸酯1%、硅氧烷三醇藻酸酯3%、甲基硅烷醇甘露糖醛酸酯5%、甘油聚醚-261.5%、大豆异黄酮1.5%、生育酚0.5%、卵磷脂1%、苯氧乙醇0.5%、羟苯甲酯0.13%、羟苯乙酯0.05%、丁二醇11.4%、羟苯甲酯钠0.01%、卡波姆0.15%、三乙醇胺0.2%、EDTA二钠0.04%、透明质酸钠0.2%、咖啡因0.2%、薯蓣根提取物1.5%、夏枯草提取物1%、积雪草提取物0.002%、虎杖根提取物0.003%、黄芩根提取物0.003%、茶叶提取物0.002%、光果甘草根提取物0.002%、母菊花提取物0.002%、迷迭香叶提取物0.002%、沉香提取物0.05%,余量为水。
所述平衡霜的制备方法如下:
S1油相制备:按重量百分比称取原料,将角鲨烷、辛酸/癸酸甘油三酯、聚二甲基硅氧烷、鲸蜡硬脂醇、鲸蜡硬脂基葡糖苷、甘油硬脂酸酯、PEG-100硬脂酸酯、硅氧烷三醇藻酸酯、甲基硅烷醇甘露糖醛酸酯、甘油聚醚-26、大豆异黄酮、生育酚、卵磷脂、苯氧乙醇、羟苯甲酯、羟苯乙酯加入油相锅中,以80转/分搅拌加热至76℃,并在76℃以50转/分搅拌30分钟,得到油相;
S2水相制备:按重量百分比称取原料,将丁二醇、羟苯甲酯钠、卡波姆、三乙醇胺、EDTA二钠和水加入水相锅中,以80转/分搅拌加热至82℃,并在82℃以80转/分搅拌20分钟,得到水相。
S3乳化:将油相和水相加入乳化锅中,在78℃以80转/分搅拌10分钟后,以4000转/分均质10分钟,再以80转/分搅拌降温至40℃,其次加入透明质酸钠、咖啡因、薯蓣根提取物、夏枯草提取物、积雪草提取物、虎杖根提取物、黄芩根提取物、茶叶提取物、光果甘草根提取物、母菊花提取物、迷迭香叶提取物、沉香提取物,以80转/分搅拌30分钟,得到平衡霜。
实施例2
按重量百分比计,平衡霜中的配方和配比为:角鲨烷7%、辛酸/癸酸甘油三酯6%、聚二甲基硅氧烷2%、鲸蜡硬脂醇1.7%、鲸蜡硬脂基葡糖苷0.4%、甘油硬脂酸酯0.9%、PEG-100硬脂酸酯1.2%、硅氧烷三醇藻酸酯4%、甲基硅烷醇甘露糖醛酸酯4%、甘油聚醚-263%、大豆异黄酮1%、生育酚2%、卵磷脂1.5%、苯氧乙醇0.4%、羟苯甲酯0.07%、羟苯乙酯0.04%、丁二醇11.7%、羟苯甲酯钠0.02%、卡波姆0.3%、三乙醇胺0.25%、EDTA二钠0.05%、透明质酸钠0.3%、咖啡因0.3%、薯蓣根提取物2.5%、夏枯草提取物2%、积雪草提取物0.004%、虎杖根提取物0.004%、黄芩根提取物0.005%、茶叶提取物0.003%、光果甘草根提取物0.004%、母菊花提取物0.004%、迷迭香叶提取物0.004%、沉香提取物0.04%,余量为水。
所述平衡霜的制备方法如下:
S1油相制备:按重量百分比称取原料,将角鲨烷、辛酸/癸酸甘油三酯、聚二甲基硅氧烷、鲸蜡硬脂醇、鲸蜡硬脂基葡糖苷、甘油硬脂酸酯、PEG-100硬脂酸酯、硅氧烷三醇藻酸酯、甲基硅烷醇甘露糖醛酸酯、甘油聚醚-26、大豆异黄酮、生育酚、卵磷脂、苯氧乙醇、羟苯甲酯、羟苯乙酯加入油相锅中,以50转/分搅拌加热至78℃,并在78℃以50转/分搅拌20分钟,得到油相;
S2水相制备:按重量百分比称取原料,将丁二醇、羟苯甲酯钠、卡波姆、三乙醇胺、EDTA二钠和水加入水相锅中,以50转/分搅拌加热至76℃,并在76℃以50转/分搅拌30分钟,得到水相。
S3乳化:将油相和水相加入乳化锅中,在76℃以50转/分搅拌15分钟后,以3000转/分均质15分钟,再以50转/分搅拌降温至45℃,其次加入透明质酸钠、咖啡因、薯蓣根提取物、夏枯草提取物、积雪草提取物、虎杖根提取物、黄芩根提取物、茶叶提取物、光果甘草根提取物、母菊花提取物、迷迭香叶提取物、沉香提取物,以50转/分搅拌40分钟,得到平衡霜。
实施例3
按重量百分比计,平衡霜中的配方和配比为:
角鲨烷6%、辛酸/癸酸甘油三酯5%、聚二甲基硅氧烷2.5%、鲸蜡硬脂醇1.6%、鲸蜡硬脂基葡糖苷0.45%、甘油硬脂酸酯0.95%、PEG-100硬脂酸酯1.1%、硅氧烷三醇藻酸酯3.5%、甲基硅烷醇甘露糖醛酸酯4.5%、甘油聚醚-262%、大豆异黄酮1.3%、生育酚1.5%、卵磷脂1.2%、苯氧乙醇0.45%、羟苯甲酯0.1%、羟苯乙酯0.045%、丁二醇11.6%、羟苯甲酯钠0.015%、卡波姆0.2%、三乙醇胺0.225%、EDTA二钠0.045%、透明质酸钠0.25%、咖啡因0.25%、薯蓣根提取物2%、夏枯草提取物1.5%、积雪草提取物0.003%、虎杖根提取物0.0035%、黄芩根提取物0.004%、茶叶提取物0.0025%、光果甘草根提取物0.003%、母菊花提取物0.003%、迷迭香叶提取物0.003%、沉香提取物0.045%,余量为水。
所述平衡霜的制备方法如下:
S1油相制备:按重量百分比称取原料,将角鲨烷、辛酸/癸酸甘油三酯、聚二甲基硅氧烷、鲸蜡硬脂醇、鲸蜡硬脂基葡糖苷、甘油硬脂酸酯、PEG-100硬脂酸酯、硅氧烷三醇藻酸酯、甲基硅烷醇甘露糖醛酸酯、甘油聚醚-26、大豆异黄酮、生育酚、卵磷脂、苯氧乙醇、羟苯甲酯、羟苯乙酯加入油相锅中,以65转/分搅拌加热至77℃,并在77℃以65转/分搅拌25分钟,得到油相;
S2水相制备:按重量百分比称取原料,将丁二醇、羟苯甲酯钠、卡波姆、三乙醇胺、EDTA二钠和水加入水相锅中,以65转/分搅拌加热至80℃,并在80℃以65转/分搅拌25分钟,得到水相。
S3乳化:将油相和水相加入乳化锅中,在77℃以65转/分搅拌13分钟后,以3500转/分均质13分钟,再以65转/分搅拌降温至42℃,其次加入透明质酸钠、咖啡因、薯蓣根提取物、夏枯草提取物、积雪草提取物、虎杖根提取物、黄芩根提取物、茶叶提取物、光果甘草根提取物、母菊花提取物、迷迭香叶提取物、沉香提取物,以65转/分搅拌35分钟,得到平衡霜。
实施例4
按重量百分比计,平衡霜中的配方和配比为:
将角鲨烷5%、辛酸/癸酸甘油三酯5%、聚二甲基硅氧烷2%、鲸蜡硬脂醇1.6%、鲸蜡硬脂基葡糖苷0.4%、甘油硬脂酸酯1%、PEG-100硬脂酸酯1%、硅氧烷三醇藻酸酯3.55%、甲基硅烷醇甘露糖醛酸酯4.9935%、甘油聚醚-26 2%、大豆异黄酮1%、生育酚1%、卵磷脂1%、苯氧乙醇0.432%、羟苯甲酯0.12%、羟苯乙酯0.045%、丁二醇11.5455%、羟苯甲酯钠0.011%、卡波姆0.2%、三乙醇胺0.2%、EDTA二钠0.05%、透明质酸钠0.2%、咖啡因0.2%、薯蓣根提取物2%、夏枯草提取物1%、积雪草提取物0.003%、虎杖根提取物0.003%、黄芩根提取物0.003%、茶叶提取物0.003%、光果甘草根提取物0.003%、母菊花提取物0.003%、迷迭香叶提取物0.003%、沉香提取物0.05%,余量为水。
所述平衡霜的制备方法如下:
S1油相制备:按重量百分比称取原料,将角鲨烷、辛酸/癸酸甘油三酯、聚二甲基硅氧烷、鲸蜡硬脂醇、鲸蜡硬脂基葡糖苷、甘油硬脂酸酯、PEG-100硬脂酸酯、硅氧烷三醇藻酸酯、甲基硅烷醇甘露糖醛酸酯、甘油聚醚-26、大豆异黄酮、生育酚、卵磷脂、苯氧乙醇、羟苯甲酯、羟苯乙酯加入油相锅中,以80转/分搅拌加热至78℃,并在78℃以80转/分搅拌25分钟,得到油相;
S2水相制备:按重量百分比称取原料,将丁二醇、羟苯甲酯钠、卡波姆、三乙醇胺、EDTA二钠和水加入水相锅中,以80转/分搅拌加热至80℃,并在80℃以80转/分搅拌25分钟,得到水相。
S3乳化:将油相和水相加入乳化锅中,在78℃以80转/分搅拌13分钟后,以3500转/分均质13分钟,再以80转/分搅拌降温至42℃,其次加入透明质酸钠、咖啡因、薯蓣根提取物、夏枯草提取物、积雪草提取物、虎杖根提取物、黄芩根提取物、茶叶提取物、光果甘草根提取物、母菊花提取物、迷迭香叶提取物、沉香提取物,以80转/分搅拌30分钟,得到平衡霜。
对比例1
不加入任何植物提取剂,其余配方和配比以及制备方法同实施例4。
对比例2
不加入迷迭香提取物,其余配方和配比以及制备方法同实施例4。
对比例3
不加入咖啡因,其余配方和配比以及制备方法同实施例4。
对比例4
不加入聚二甲基硅氧烷,其余配方和配比以及制备方法同实施例4。
对比例5
羟苯甲酯的含量改为0.18%,其余配方配比以及制备方法同实施例4。
对比例6
将PEG-100硬脂酸酯的含量改为2.2%,其余配方配比以及制备方法同实施例4。
对比例7
某市售的调节女性荷尔蒙的平衡霜
二、效果验证。
(一)外观及稳定性测试。
将实施例1-4所得的产品与对比例7的市售产品分别置于50℃和-15℃下存放24h,其后恢复至室温,观察平衡霜的形态,测试结果如表1所示。
表1外观及稳定性测试结果
通过表1可知:本发明中制备的平衡霜质地细腻,粘度适中,且在50℃以及-15℃下存放24h后恢复常温依然能够持续原有状态,体现了本发明中的平衡霜稳定性极易外观均较好;而市售的平衡霜在常温下虽然能够保持较好的外观以及稳定性,但是放置在高温或者低温下其外观会发生变化,难以恢复至原始状态,外观以及稳定性较本发明差。
(二)人体皮肤斑贴试验皮肤。
选取80名女性志愿者,平均分为8组,8组测试者对应实施例1-4和对比例1、5-7中的8种平衡霜。参照《化妆品安全技术规范(2015版)》对8种平衡霜进行《人体皮肤斑贴试验》,测试标准如表2所示,测试结果如表3所示。
表2皮肤反应分级标准
表3
产品 | 评分等级 |
实施例1 | 0 |
实施例2 | 0 |
实施例3 | 0 |
实施例4 | 0 |
对比例1 | 1-2 |
对比例5 | 1 |
对比例6 | 1 |
对比例7 | 0 |
通过表3可知:本发明中的平衡霜以及市售的平衡霜均对皮肤无任何刺激,均呈阴性,而对比例1中未加入中药提取物,其测出的皮肤等级相对较高,对比例5和对比例6中平衡霜因未按照本发明中的配比配制,其对于皮肤具有一定的刺激作用,但整体较轻微,进而体现出本发明中的配比关系的优越性,另外,本发明中的中药提取物的抗菌消炎性能与防腐剂或者乳化剂中的致过敏或者致痘物质进行复配后能够克服致痘或者致敏风险,因此配比关系在本发明中极为重要。
(三)祛痘效果测试
选取80名年龄在15-30岁、且面部均有皮损(丘疹、脓包)的志愿者。每10名志愿者为一组,共分为8组,8组测试者分别对应实施例1-4和对比例1、5-7的8种平衡霜。
测试方法:洁面后,每组志愿者分别取对应的平衡霜涂抹在痘处,轻轻按摩至完全吸收,每天早晚各一次,连续使用60天。
疗效评价标准:
疗效=(治疗前皮损计数-治疗后皮损计数)/治疗前皮损计数×100%
A显效:皮损消退60%~90%,症状减轻;
B有效:皮损消退20%~60%,症状改善;
C无效:皮损消退<20%,临床症状未改善;
治疗结果如表4所示:
产品 | 使用15天 | 使用30天 | 使用45天 | 使用60天 |
实施例1 | 丘疹C、脓包C | 丘疹B、脓包C | 丘疹B、脓包B | 丘疹A、脓包B |
实施例2 | 丘疹C、脓包C | 丘疹B、脓包C | 丘疹B、脓包B | 丘疹A、脓包B |
实施例3 | 丘疹B、脓包C | 丘疹B、脓包C | 丘疹B、脓包B | 丘疹A、脓包B |
实施例4 | 丘疹B、脓包C | 丘疹B、脓包B | 丘疹A、脓包B | 丘疹A、脓包A |
对比例1 | 丘疹C、脓包C | 丘疹C、脓包C | 丘疹C、脓包C | 丘疹C脓包C |
对比例5 | 丘疹C、脓包C | 丘疹C、脓包C | 丘疹C、脓包C | 丘疹C、脓包C |
对比例6 | 丘疹C、脓包C | 丘疹C、脓包C | 丘疹C、脓包C | 丘疹C、脓包C |
对比例7 | 丘疹C、脓包C | 丘疹C、脓包C | 丘疹B、脓包C | 丘疹B、脓包C |
通过表4可知,本发明中的平衡霜对于丘疹和脓包具有一定的疗效,其显效时长和治疗效果与市售的祛痘平衡霜相当,且随着时间的延长,治疗效果呈递增趋势,且实施例4中的平衡霜治疗效果优于市售的祛痘平衡霜,具有显著的效果;而对比例1中因未添加植物提取物,其在祛痘方面的疗效几乎没有,且对受试者持续观察发现,40%的受试者还出现爆痘的情况,对比例5和对比例6中的平衡霜因未按照本发明中的配比制备,其在治痘方面的性能较弱,未发现明显的疗效,且有20%的受试者出现爆痘的情况;市售的平衡霜在祛痘方面的效果不明显。
(四)抑菌效果测试。
将实施例1-4和对比例1、7进行抑菌试验,检测对对大肠杆菌、金黄色葡萄球菌和白色念珠球菌的抑菌效果,结果如表5所示。
表5
由表5可知:
本发明中的平衡霜对金黄色葡萄球菌、大肠杆菌和白色念球菌具有明显的抑菌活性,抑菌效果好;而对比例1中的平衡霜因未添加植物提取物,其抑菌性能明显较低,体现了中药提取物在平衡霜中具有极强的抑菌效果;对比例7中的平衡霜抑菌效果相较对比例好,但是远远差于本发明中的平衡霜。通过表5和表6可知,平衡霜中的抑菌成分与祛痘具有极大的关联性。
(五)保湿性测试
选取60名女性志愿者,平均分为6组,6组测试者对应实施例1-4和对比例1、7中的6种平衡霜。
测试方法:测试环境温度为28℃,相对湿度为60%,测定前将被测者的脸部清洗干净并擦干,在测试者的脸部同一位置选择2cm×2cm的区域,并涂抹相同体积的对应平衡霜轻轻按摩至吸收后,使用皮肤水分测试仪测定试验区域的皮肤水分含量,记录结果为Ao,在8小时时测试皮肤水分含量,记录结果为A1,计算:皮肤水分增加量=[(A1-A0)/A0]×100%,测试结果如表6所示:
表6
通过表6可知,本发明中的平衡霜在保湿性方面和市售的保湿平衡霜具有相当的效果,体现了本发明的优越性,其次,对比例1中的平衡霜未添加中药提取物,其保湿效果较差,对比例8中的祛痘平衡霜侧重治疗性,因此在护理方面的效果较差。
(六)消肿测试
选取10名早上起床后脸部易水肿的志愿者,进行消肿测试。
测试方法为:取实施例1-4和对比例1、2、3、7中的8种平衡霜,让10名志愿者每天早上涂抹其中一种平衡霜,并记录消肿时间,每8天为一个循环,连续测试3个循环后,记录消肿平均时间,测试结果如表7所示:
表7
平均消肿时间(min) | |
实施例1 | 30-60 |
实施例2 | 45-65 |
实施例3 | 35-70 |
实施例4 | 25-60 |
对比例1 | 120-200 |
对比例2 | 120-200 |
对比例3 | 120-200 |
对比例7 | 120-200 |
不使用任何平衡霜 | 150-250 |
通过表7可知,本发明中的平衡霜有明显的的消肿效果,而未加入咖啡因或者迷迭香等植物提取剂的平衡霜无明显消肿效果;由此可说明咖啡因和植物提取剂之间发生协同作用时能够发挥消肿作用。
(七)香度残留测试
选取40名志愿者,进行香度残留测试,每5名志愿者为一组,每组志愿者分别在手腕内侧涂抹等量实施例1-4和对比例1、2、3、4中的一种平衡霜,持续对香味进行测试。
测试结果如表8所示:
表8
第2h | 第4h | 第6h | 第8h | |
实施例1 | 香味浓郁 | 香味浓郁 | 香味浓郁 | 香味减弱 |
实施例2 | 香味浓郁 | 香味浓郁 | 香味浓郁 | 香味减弱 |
实施例3 | 香味浓郁 | 香味浓郁 | 香味浓郁 | 香味减弱 |
实施例4 | 香味浓郁 | 香味浓郁 | 香味浓郁 | 香味减弱 |
对比例1 | 无明显香味 | 无明显香味 | 无明显香味 | 无明显香味 |
对比例2 | 香味浓郁 | 香味浓郁 | 香味浓郁 | 香味减弱 |
对比例3 | 香味浓郁 | 香味浓郁 | 香味浓郁 | 香味减弱 |
对比例4 | 香味浓郁 | 香味减弱 | 香味明显减弱 | 香味不明显 |
通过表8可知:本发明中的平衡霜香度残留时间较长,因此其能持续激发人体荷尔蒙的释放;通过对比例4可知,未加入聚二甲基硅氧烷时,平衡霜的固香能力明显减弱。
(八)总体治疗效果
为了进一步验证本发明制备的平衡霜的治疗效果,征集280名女性荷尔蒙失调的志愿者,年龄为20-50岁。将280例志愿者随机平均分成七组,分别对应使用实施例1-4和对比例1、2和7中的共7种平衡霜进行测试,在使用过程中,均配合中医推拿按摩手法进行每周3次临床治疗,治疗观察期为6个月。7组志愿者的年龄、病程、病情等资料无显著性差异,具有可比性。
其中,治疗效果的判定标准如下:
显效:荷尔蒙失调症状明显改善;有效:荷尔蒙失调症状有所改善;无效:使用前后对比症状无改善。
治疗结果如表9所示。
表9
通过表9可知,本发明中的平衡霜有明显的治疗效果,其总体治疗效果远高于未加入中药提取物或者未按照本发明中的配方进行配置的平衡霜,同时本发明中的平衡霜效果比市售的调节荷尔蒙的效果更好,体现本发明中的平衡霜具有明显调节女性荷尔蒙的效果。
此外,对280位志愿者进行跟踪发现,停止治疗3个月后,实施例1-4中的志愿者均未感觉症状有反复、恶化或加重,而对比例1、2和7的志愿者均感觉症状存在一定的反复现象。足以证明,本发明中的平衡霜具有明显的长效性。
总结:通过表1-表9可知,本发明中的平衡霜在调节、改善和平衡女性荷尔蒙方面发挥极为显著的效果,此外,其在抗菌、保湿、消肿、祛痘、固香等方面也均发挥了极为显著的效果,且其质地细腻,稳定性良好,能够广泛适用各类女性荷尔蒙失调人群,且能够作为面霜使用;未按照本发明中的配方或者配比制备的平衡霜,其各项性能均有所下降,体现出本发明中的配方和配比的优越性。
以上仅是本发明的优选实施方式,应当理解本发明并非局限于本文所披露的形式,不应看作是对其他实施例的排除,而可用于各种其他组合、修改和环境,并能够在本文构想范围内,通过上述教导或相关领域的技术或知识进行改动。而本领域人员所进行的改动和变化不脱离本发明的精神和范围,则都应在本发明所附权利要求的保护范围内。
Claims (8)
1.一种调节荷尔蒙的沉香平衡霜,其特征在于,所述平衡霜的组分及质量比为:硅氧烷三醇藻酸酯3-4%、咖啡因0.2-0.3%、羟苯甲酯钠0.01-0.02%、甲基硅烷醇甘露糖醛酸酯4-5%、甘油聚醚-26 1.5-3%、大豆异黄酮1-1.5%、生育酚0.5-2%、卵磷脂1-1.5%、薯蓣根提取物1.5-2.5%、夏枯草提取物1-2%、积雪草提取物0.002-0.004%、虎杖根提取物0.003-0.004%、黄芩根提取物0.003-0.005%、茶叶提取物0.002-0.003%、光果甘草根提取物0.002-0.004%、母菊花提取物0.002-0.004%、迷迭香叶提取物0.002-0.004%、沉香提取物0.04-0.05%、透明质酸钠0.2-0.3%、丁二醇11.4-11.7、角鲨烷5-7%、辛酸/癸酸甘油三酯4-6%、聚二甲基硅氧烷2-3%、卡波姆0.15-0.3%、三乙醇胺0.2-0.25%、EDTA二钠0.04-0.05%、防腐剂0.51-0.65%、乳化剂3-4.5%、余量为水。
2.根据权利要求1所述的一种调节荷尔蒙的沉香平衡霜,其特征在于,所述平衡霜的组分及质量比为:硅氧烷三醇藻酸酯3.55%、咖啡因0.2%、羟苯甲酯钠0.011%、甲基硅烷醇甘露糖醛酸酯4.9935%、甘油聚醚-26 2%、大豆异黄酮1%、生育酚1%、卵磷脂1%、薯蓣根提取物2%、夏枯草提取物1%、积雪草提取物0.003%、虎杖根提取物0.003%、黄芩根提取物0.003%、茶叶提取物0.003%、光果甘草根提取物0.003%、母菊花提取物0.003%、迷迭香叶提取物0.003%、沉香提取物0.05%、透明质酸钠0.2%、丁二醇11.5455%、角鲨烷5%、辛酸/癸酸甘油三酯5%、聚二甲基硅氧烷2%、卡波姆0.2%、三乙醇胺0.2%、EDTA二钠0.05%、防腐剂0.6%、乳化剂4%、余量为水。
3.根据权利要求1所述的一种调节荷尔蒙的沉香平衡霜,其特征在于,所述防腐剂的组分及其在所述平衡霜中的质量比为:苯氧乙醇0.4-0.5%、羟苯甲酯0.07-0.13%、羟苯乙酯0.04-0.05%。
4.根据权利要求3所述的一种调节荷尔蒙的沉香平衡霜,其特征在于,所述防腐剂的组分及其在所述平衡霜中的质量比为:苯氧乙醇0.432%、羟苯甲酯0.12%、羟苯乙酯0.048%。
5.根据权利要求1所述的一种调节荷尔蒙的沉香平衡霜,其特征在于,所述乳化剂的组分及其在所述平衡霜中的质量比为:鲸蜡硬脂醇1.5-1.7%、鲸蜡硬脂基葡糖苷0.4-0.5%、甘油硬脂酸酯0.9-1%、PEG-100硬脂酸酯1-1.2%。
6.根据权利要求5所述的一种调节荷尔蒙的沉香平衡霜,其特征在于,所述乳化剂的组分及其在所述平衡霜中的质量比为:鲸蜡硬脂醇1.6%、鲸蜡硬脂基葡糖苷0.4%、甘油硬脂酸酯1%、PEG-100硬脂酸酯1%。
7.根据权利要求1所述的一种调节荷尔蒙的沉香平衡霜的制备方法,其特征在于,包括如下步骤:
S1油相制备:按重量百分比称取原料,将角鲨烷、辛酸/癸酸甘油三酯、聚二甲基硅氧烷、乳化剂、硅氧烷三醇藻酸酯、甲基硅烷醇甘露糖醛酸酯、甘油聚醚-26、大豆异黄酮、生育酚、卵磷脂、防腐剂加入油相锅中,以50-80转/分搅拌并同时加热至76-78℃,其后在76-78℃以50-80转/分搅拌20-30分钟,得到油相;
水相制备:按重量百分比称取原料,将丁二醇、羟苯甲酯钠、卡波姆、三乙醇胺、EDTA二钠和水加入水相锅中,以50-80转/分搅拌并同时加热至76-82℃,其后在76-82℃以50-80转/分搅拌20-30分钟,得到水相;
S2乳化:将所述油相和水相加入乳化锅中,在76-78℃以50-80转/分搅拌10-15分钟后,以3000-4000转/分均质10-15分钟,再以50-80转/分搅拌并降温至40-45℃,其次加入透明质酸钠、咖啡因、薯蓣根提取物、夏枯草提取物、积雪草提取物、虎杖根提取物、黄芩根提取物、茶叶提取物、光果甘草根提取物、母菊花提取物、迷迭香叶提取物和沉香提取物,以50-80转/分搅拌30-40分钟,得到平衡霜。
8.根据权利要求1所述的一种调节荷尔蒙的沉香平衡霜的运用,其特征在于,用于调节女性荷尔蒙。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111669339.7A CN114515265A (zh) | 2021-12-31 | 2021-12-31 | 一种调节荷尔蒙的沉香平衡霜及其制备方法和运用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111669339.7A CN114515265A (zh) | 2021-12-31 | 2021-12-31 | 一种调节荷尔蒙的沉香平衡霜及其制备方法和运用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114515265A true CN114515265A (zh) | 2022-05-20 |
Family
ID=81596288
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111669339.7A Pending CN114515265A (zh) | 2021-12-31 | 2021-12-31 | 一种调节荷尔蒙的沉香平衡霜及其制备方法和运用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114515265A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108379155A (zh) * | 2018-04-20 | 2018-08-10 | 安徽怡人生物科技有限公司 | 一种祛痘霜及其制作方法 |
-
2021
- 2021-12-31 CN CN202111669339.7A patent/CN114515265A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108379155A (zh) * | 2018-04-20 | 2018-08-10 | 安徽怡人生物科技有限公司 | 一种祛痘霜及其制作方法 |
Non-Patent Citations (1)
Title |
---|
广州芳利医药科技有限公司: "一木承芳沉香平衡霜", pages 1 - 2, Retrieved from the Internet <URL:https://hzpba.nmpa.gov.cn/gccx/chakan.html?prodId=901481950584242176&gb=G> * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103237555B (zh) | 外用皮肤护理制剂 | |
CN109288764B (zh) | 一种纯露喷雾及其制备方法 | |
CN103976906B (zh) | 一种具有保湿消炎作用的植物提取液混合物 | |
CN109044941B (zh) | 一种皮肤紧致滋养保湿组合物及其制备方法和应用 | |
CN111529477A (zh) | 一种用于护理头发的组合物及其制剂和应用 | |
CN111419773A (zh) | 一种皮肤抗衰修复植物提取物组合物及应用与含该组合物的精华乳 | |
CN114246817A (zh) | 一种祛皱组合物及其制备方法和应用 | |
Venesia et al. | Effectiveness test of Centella asiatica extract on improvement of collagen and hydration in female white rat (Rattus Norwegicus Wistar) | |
CN111529450A (zh) | 深层补水修复组合物,其护肤品及制备方法 | |
CN110302128A (zh) | 一种富含天然产物提取成分的美白抗敏舒缓睡眠面膜及其制备方法 | |
CN109939193A (zh) | 一种治疗皮肤湿疹的组合物,制剂及制备方法和应用 | |
CN106511211A (zh) | 一种抗炎祛痘护肤乳液及其制备方法 | |
CN116459169B (zh) | 一种抗炎保湿皮肤外用组合物及其制备方法和应用 | |
CN112516025A (zh) | 一种具有透皮吸收功效的植物提取组合物乳霜及其制备方法 | |
CN108703911B (zh) | 一种具有保湿美白功效的组合物及其制备方法和应用 | |
CN110721101A (zh) | 一种可自行调配的双组份精华霜及其制备方法 | |
CN114515265A (zh) | 一种调节荷尔蒙的沉香平衡霜及其制备方法和运用 | |
CN113081933A (zh) | 祛痘组合物及其制备方法与应用 | |
CN113278477A (zh) | 一种美白保湿滋润抑菌的沐浴皂及其制备方法 | |
CN106511213A (zh) | 一种具备植物提取液的化妆品 | |
KR100574233B1 (ko) | 피부 보습 및 항자극 효과를 가지는 식물 혼합추출물을함유하는 화장료 조성물 | |
CN111939097A (zh) | 一种保湿舒敏组合物及其应用 | |
CN110051761A (zh) | 祛痘消炎的外用药剂及其制备方法 | |
CN110075178A (zh) | 一种治疗激素性皮炎的组合物,制剂及制备方法和应用 | |
KR20200008289A (ko) | 인설 예방 및 완화용 한약재 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20220520 |